GH - Public offerings

Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening Expects full year 2026 total revenue to grow in the range of 27% to 30% year-over-year Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $281.3 million, an increase of 39%, driven by: Oncology revenue of $189.9 million, an increase of 30%, and approximately 79,000 oncology tests, an increase of 38% Biop

Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 3,333,333 shares of Guardant Health's common stock at a public offering price of $90.00 per share (the "common stock offering"). The size of the common stock offering was increased from the previously announced $250.0 million of shares of common stock. In addition, Guardant Health granted the underwriters an option to purchase up to an additional 499,999 shares of common stock at the public offering price, less underwriting discounts and commissions. The common stock offering is expected to close on November 7, 2025, subject

Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% convertible senior notes due 2033 (the "notes") in a private offering (the "convertible notes offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the convertible notes offering was increased from the previously announced offering size of $300.0 million. The issuance and sale of the notes are scheduled to settle on November 7, 2025, subject to custom

Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health's common stock (the "common stock offering"). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The common stock offering is subject to market and other conditions, and there can be no assurance as to whether or when the common stock offering may be completed or as to the actual size or terms of the common stock offer

Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the "notes") in a private offering (the "convertible notes offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Guardant Health also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $45.0 million aggregate principal amount

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share. Gross proceeds are approximately $90.7 million, before deducting expenses payable by Guardant Health. Guardant Health intends to use the net proceeds from the offering primarily for general corporate purposes, including working capital, operating expenses and capital expenditures. "We are proud to be supported by Baillie Gifford," said Helmy Eltoukhy, co-foun

Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights Revenue of $137.2 million for the second quarter of 2023, an increase of 26% over the second quarter of 2022 Reported 43,500 tests to clinical customers and 6,700 tests to biopharmaceutical customers in the second quarter of 2023, representing increa

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions. In addition, Guardant Health has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Guardant Health, are expected to be $350.0 million, excluding

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that it has commenced an underwritten public offering of $250.0 million of its common stock. In addition, Guardant Health intends to grant the underwriters a 30-day option to purchase up to $37.5 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by Guardant Health. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. J.P. Mor

SEOUL, Souh Korea, July 19, 2021 /PRNewswire/ -- Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company. The deal, which includes the investment made by Guardant Health and also a groundbreaking collaboration between a liquid biopsy company and a medical AI startup, is intended to help reshape and innovate the precision oncology landscape. Lunit has closed its Series C Tranche B funding round with the investment from Guardant Health. Lunit i

SEOUL, Souh Korea, July 19, 2021 /PRNewswire/ -- Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of $26 million from Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company. The deal, which includes the investment made by Guardant Health and also a groundbreaking collaboration between a liquid biopsy company and a medical AI startup, is intended to help reshape and innovate the precision oncology landscape. Lunit has closed its Series C Tranche B funding round with the investment from Guardant Health. Lunit is